Pharma Talk

Showing posts with the label GMP inspections 2026FDA Warning Letters pharmaEMA MRA veterinary productscGMP compliance best practicesAsbestos testing talc OTC drugsQuality Unit oversight FDATGA GMP certificates AustraliaPharmaceut

Latest GMP Inspections and Audits Roundup: Key Compliance Lessons for Pharma Professionals (July 2026 Edition)

Sayed Mahaboob Subhani July 02, 2026

In the fast-evolving world of pharmaceutical manufacturing, staying ahead of regulatory inspections…

Pharma Talk

Latest GMP Inspections and Audits Roundup: Key Compliance Lessons for Pharma Professionals (July 2026 Edition)

Latest FDA Insights: Critical Data Integrity and OOS Issues in Recent GMP Inspections (December 2025 Update)

Analytical Method Performance USP 1221

Guidance Documents on Variation Notifications Updated

FDA Warning Letter Highlights Critical Gaps in Analytical Testing and CGMP Oversight at Taiwanese OTC Manufacturer

WHO Draft Guidance on Quality Risk Management: Practical Insights for Lifecycle Application

What is PDCA Cycle

Contact Form